http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008122425-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28a86cc76c4efbe9b409f6bf078aecf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb393daf514a121ee19dfcd32442fae4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae1390871a1335490b1390226b4cd87c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec85ff1f496d54cdcc2b94c242ad0bf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67bf14ac23872dae5fd327b65511be81
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13
filingDate 2008-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a462aad0b8f2632ac4bd9a029d457691
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ad9e7c92b33a64d1fec358a3cf167fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cef833150359eaadca7fb2fd2f2d1af0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd2e095923c4ef5fd69f0bf0e8b5167b
publicationDate 2009-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008122425-A3
titleOfInvention Oral compositions containing tacrolimus in amorphous form
abstract Fast release or modified release oral compositions containing as the active principle Tacrolimus and/or derivatives thereof in amorphous form, and: a) a 'solubilising agent' of the active principle suitable to maintain it in the amorphous form over time, b) at least one 'diluting agent' having the function to stabilize the active principle in the amorphous form, c) at least one agent being 'modulator' of the dissolution rate of the active principle from the pharmaceutical form. These compositions in form of paste, granules, powder, solution, suspension can be formulated in hard or soft gelatine capsules or can be formulated in other pharmaceutical forms for oral use. These compositions are characterized in that all the relative operations of preparation are carried out in the absence of water and/or organic solvents.
priorityDate 2007-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1092429-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005020994-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1064942-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006062334-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445643
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136015015
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395352
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439492

Total number of triples: 34.